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Abstract
Background. Albuminuria, heart rate (HR) and blood pressure are established predictors of chronic kidney disease 
and cardiovascular disease. The objective of this study was to explore the relationship between HR, systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) with renal function parameters in patients with type 1 diabetes 
(T1DM) without therapeutical interventions.
Material and methods. Study included 313 normoalbuminuric T1DM. HR was determined using a standard 
12-lead ECG and blood pressure with a mercury sphygmomanometer, both after a resting period of 10 minutes. 
Urinary albumin excretion rate (UAE) was measured from at least two 24-h urine samples. Data on serum creatini-
ne levels, age, sex and race were used to calculate the estimated glomerular filtration rate (eGFR) using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
Results. eGFR was significantly associated with duration of diabetes, HbA1c, LDL-cholesterol, and HDL-choles-
terol (for the duration of diabetes r = –0.29, p < 0.001). UAE significantly correlated with duration of diabetes,  
HDL-cholesterol, triglycerides, HR and DBP (for HR and DBP r = 0.21–0.23, p < 0.001). Subjects in the 4th quar-
tile of UAE had significantly higher HR rate compared to subjects in 1st, 2nd, and 3rd quartiles (70 ± 11 vs. 74 ± 12 
vs. 74 ± 12 vs. 79 ± 13 beats/min, p = 0.001).
Conclusions. Results of our study suggest that interplay between HR with renal function parameters is present even 
in T1DM with normal renal function.
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Introduction
Diabetes mellitus is the most common cause of 
chronic kidney disease in the world [1]. Patients 
with diabetes, in order to prevent development or 
progression of renal disease, need strict control of 
risk factors, which includes not only good glycemic 
control but also optimal lipid and blood pressure 
control [2]. Heart rate (HR) is an easily measurable 
biological parameter for which determination simple 
instruments are required. HR is generally considered 
to be an unreliable biological marker in epidemio-
logical studies because it depends on the methods 
and conditions under which it is measured and it is 
also often underestimated in the clinical setting [3]. 
Although the HR has its clear limitations, there are 
studies that clearly showed the association between 
resting HR and the chronic kidney disease in pa-
tients with type 1 and type 2 diabetes. Schmieder et 
al. [4] and Hillis et al. [5] connected elevated resting 
HR with an increased risk of microalbuminuria in 
patients with type 2 diabetes, while Choe et al. [6] 
connected elevated resting HR in adolescents with 
elevated albuminuria. Moreover, there is an evident 
association between resting HR and mortality in 
patients with hypertension, coronary heart disease 
and patients with left ventricular systolic dysfunc-
tion [7–10].
In addition to HR, elevated systolic blood pres-
sure (SBP) and diastolic blood pressure (DBP) are 
associated with the development of chronic kidney 
disease and with increased mortality in patients with 
and without diabetes [11, 12]. Moreover, elevated 
blood pressure, as well as its oscillations, are with 
diabetes the most important cause of the develop-
ment and progression of chronic kidney disease [13, 
14]. On the other hand, the development of chronic 
kidney disease in patients with diabetes highly in-
creases the risk of developing cardiovascular diseases 
and mortality [15].
The risk of development of microalbuminuria can 
be predicted by changes in urinary albumin excre-
tion (UAE), which is still within the physiological 
range [16]. Microalbuminuria is considered to be 
the earliest stage of renal disease in patients with 
diabetes and the therapeutic approach is based on 
providing a therapy that will prevent the develop-
ment and progression of microalbuminuria. Recently 
published 5-year retrospective analysis showed a 21% 
cumulative incidence of chronic kidney disease in 
a large cohort of patients with type 1 diabetes mel-
litus (T1DM) with preserved kidney function at 
baseline and with nearly 4% of patients developing 
renal impairment and 18% developing albuminuria 
[17]. The aim of this study was to explore the rela-
tionship between HR and blood pressure with renal 
function parameters in T1DM without therapeutical 
interventions.
Material and methods
This study included 313 patients with type 1 diabetes 
defined according to the age of diagnosis (below 35 
years), autoantibodies positivity and insulin treat-
ment initiated within 1 year of diagnosis. The study 
included patients with minimum duration of dia-
betes of 1 year and age between 18–65 years. We 
excluded from the study patients that were treated 
with antihypertensive therapy and lipid-lowering 
therapy. We also excluded from the study patients 
with acute and chronic inflammation.
Basic anthropometric measurements were per-
formed on all study subjects. HR was determined 
using a standard 12-lead ECG and blood pressure 
with a mercury sphygmomanometer, both after a re-
sting period of 10 minutes. Urinary albumin excre-
tion rate (UAE) was determined as the mean of 24-h 
urine collections measured from at least two 24-h 
urine samples. We excluded from the study patients 
with microalbuminuria (UAE ≥ 30 < 300 mg/24 h), 
macroalbuminuria (UAE ≥ 300 mg/24 h) and those 
with estimated glomerular filtration rate (eGFR) 
less than 60 ml min-1 1.73 m-2 calculated using the 
Chronic Kidney Disease Epidemiology Collabora-
tion (CKD-EPI) formula [18, 19].
Hemoglobin A1c (HbA1c) and serum lipids were 
determined in all patients after an overnight fast. 
Microalbumin and HbA1c were measured spectro-
photometrically by turbidimetric immuno-inhibi-
tion (Olympus AU600, Beckman-Coulter, USA). 
Serum lipids were measured by an enzymatic co-
lourimetric method.
Data are expressed as means ± SD for normally 
distributed values, as median with range for non-
normally distributed values, and percentage. Pear-
son’s correlation coefficients were used to calculate 
correlations between normally distributed values and 
Spearman’s rank correlation coefficients were used for 
non-normally distributed values. To investigate the re-
lationship between HR and blood pressure with renal 
function parameters data were also stratified in quar-
tiles depending on UAE as well as in different groups 
of eGFR. Kruskal-Wallis test was used for calculating 
the significance of the trend for each variable among 
the different groups. Level of statistical significance 
was chosen to be a = 0.05. Statistical analysis was 
performed by statistical package STATA/IC ver.11.1.
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Results
The characteristics of the study subjects are listed in 
Table I. Mean/median values of BMI, HDL-choles-
terol, triglycerides, serum creatinine, UAE, eGFR, 
HR as well as blood pressure were within the normal 
range for patients with diabetes, with slightly elevat-
ed HbA1c and LDL-cholesterol levels. Correlations 
between renal function parameters and HR, blood 
pressure and metabolic parameters are presented 
in Table II. eGFR was significantly associated with 
duration of diabetes, HbA1c, LDL-cholesterol, and 
HDL-cholesterol, with duration of diabetes showing 
the strongest correlation (r = –0.29, p < 0.001). UAE 
was significantly associated with duration of diabe-
tes, HDL-cholesterol, triglycerides, HR and DBP, 
with HR and DBP showing the strongest correlation 
(r = 0.21–0.23, p < 0.001).
The relationship between blood pressure and HR 
among those in the 2nd, 3rd and 4th quartiles of UAE 
compared to those in quartile 1 are presented in 
Table III. Stratifying blood pressure and HR for the 
degree of UAE, trends across quartiles of UAE for 
HR was statistically significant (p = 0.001). Subjects 
in the 4th quartile of UAE had significantly higher 
HR compared to subjects in 1st, 2nd, and 3rd quartiles. 
We also explore the relationship between blood pres-
sure and HR according to the level of eGFR. Stratify-
ing blood pressure and HR for the degree of eGFR, 
trends were not statistically significant for HR and 
blood pressure (Tab. IV). 
Discussion
This cross-sectional study investigated the causal re-
lationship between renal function parameters and 
Table I. Clinical and metabolic characteristics of all patients
Variable Value
Age (years) 
Duration of diabetes (years)
BMI [kg/m2]
HbA1c (%)
SBP [mm Hg] 
DBP [mm Hg]
Heart rate (beats/min) 
LDL cholesterol [mmol/L] 
HDL cholesterol [mmol/L] 
Triglycerides [mmol/L]
Serum creatinine [µmol/L]
eGFR [mL min–1 1.73m-2]
UAE [mg/24 h]
34 (18–65)
12 (1–42)
24 (15–37)
7.43 ± 1.63
120 (79–180)
80 (50–100)
74 ± 13
2.8 ± 0.7
1.7 ± 0.4
0.91 (0.3–4.1)
71 ± 14
106 ± 16
11.0 (1.7–29.8)
BMI — body mass index; HbA1c — hemoglobin A1c; SBP — systolic blood pressure; DBP — diastolic 
blood pressure; LDL — low density lipoprotein; HDL — high density lipoprotein; eGFR — estimated 
glomerular filtration rate; UAE — urinary albumin excretion
Table II. Correlation analysis of associations of renal function 
parameters with heart rate, blood pressure and metabolic para-
meters
Variable UAE eGFR
Duration of diabetes
BMI 
HBA1c 
LDL cholesterol
HDL cholesterol 
Triglycerides 
SBP 
DBP 
Heart rate 
0.14*
–0.02
0.07 
0.03 
–0.13*
0.11*
0.09 
0.23* 
0.21* 
–0.29*
–0.10
0.15*
–0.18*
–0.17*
0.06
–0.08
–0.01
0.21
UAE — urinary albumin excretion rate; GFR — estimated glomerular filtration rate; BMI — body mass 
index; HbA1c — haemoglobin A1c; LDL — low density lipoprotein; HDL — high density lipoprotein; 
SBP — systolic blood pressure; DBP — diastolic blood pressure; *p < 0.05
Table III. Quartiles of urinary albumin excretion rate 
1st quartile 
(< 6.8 mg/24 h)
2nd quartile
(≥ 6.8 < 11.0)
3rd quartile
(≥ 11.0 < 16.7)
4th quartile
(≥ 16.7 mg/24 h)
p
for trend
Heart rate (beats/min) 70 ± 11 74 ± 12 74 ±12 79 ± 13 0.001
SBP [mm Hg] 120 (90–145) 120 (90–180) 120 (90–170) 120 (80–180) 0.19
DBP [mm Hg] 80 (60–90) 80 (60–90) 80 (60–110) 80 (50–110) 0.1
SBP — systolic blood pressure; DBP — diastolic blood pressure
Table IV. Blood pressure and heart rate depending on the level of estimated glomerular filtration rate
Variable eGFR [mL min-1 1.73 m–2] p
> 60 ≤ 90 > 90 ≤ 125 > 125
Heart rate (beats/min) 74 ± 12 73 ± 12 78 ± 16 0.3
SBP [mm Hg] 120 (80–170) 120 (90–180) 120 (90–140) 0.7
DBP [mm Hg] 80 (65–10) 80 (60–110) 80 (50–90) 0.1
SBP — systolic blood pressure; DBP — diastolic blood pressure
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blood pressure and HR in T1DM who were not 
taking any other therapy (antilipidemic or antihy-
pertensive) except insulin. In correlation analysis, the 
strongest correlations were recorded between HR, 
DBP and UAE. Moreover, after stratifying blood 
pressure and HR for the degree of UAE, trends across 
quartiles of UAE for HR was statistically significant 
(p = 0.001) in our patients with normoalbuminuria. 
All our studied patients have normal renal func-
tion according to eGFR and albuminuria. However, 
it is increasingly being examined whether there is 
a safe level of albumin excretion in the urine. Several 
studies showed that in non-diabetic patients as well as 
in those with diabetes, a higher normal UAE predicts 
the development of cardiovascular and renal adverse 
events [20, 21]. Consequently, there is a growing 
prevalence of an opinion that the UAE should be ob-
served as a continuous variable [22]. Our study can-
not conclude about the causal relationship between 
high normal UAE and future renal impairment, but 
it does show that subgroups of different UAE, which 
may be correlated with different parameters, exist 
within the group of normoalbuminuric T1DM. In 
addition, in normoalbuminuric type 2 diabetic pa-
tients, the UAE is correlated with many factors that 
are potentially susceptible to intervention [23].
Heart Rate is a strong and independent predic-
tor of major cardiovascular complications including 
myocardial infarction, heart failure, cardiac death, 
and stroke and also with all-cause mortality in sub-
jects with and without diabetes [24, 25]. It is also 
documented that higher HR is associated with in-
creased prevalence and severity of microalbuminuria 
and that HR and microalbuminuria were each inde-
pendently associated with the composite endpoint 
of all-cause death, myocardial infarction, and stroke 
[26, 27]. Histological studies in humans showed 
that the renal endings of sympathetic fibres are not 
only in contact with the kidney vasculature, but also 
with renal tubules and juxtaglomerular cells, while 
animal models showed that these neural endings 
are involved in hemodynamic regulation, tubular 
transport, and renin secretion [28, 29]. Increased 
sympathetic activity in humans have a deleterious 
effect on renal function, regardless of the accompa-
nying hypertension [30]. The highest influence of 
the sympathetic nervous system is precisely on the 
podocytes. Although adrenergic fibers do not reach 
to glomerulus [31], podocytes possess adrenergic re-
ceptors [32]. Adrenergic receptors on podocytes me-
diate calcium influx in the podocytes, causing their 
contraction and decreasing their selective bandwidth 
[32]. It is suggested that these possible mechanisms 
of increased sympathetic activity are associated with 
higher UAE. It is well known that the resting HR 
is determined by the activity of the sinus node and 
that resting HR may serve as an indicator of sym-
pathetic hyperactivity or insufficient vagal activity 
[33]. In our study, there is no information whether 
the increased sympathetic activity precedes increased 
UAE in the normal range or whether there is an 
inverse relationship of causality, but results clearly 
shows that there are signs of increased sympathetic 
activity in the group of patients with higher UAE. 
However, it has been shown that cardiac autonomic 
neuropathy is an independent risk factor for car-
diovascular morbidity and mortality in T1DM with 
nephropathy, but not in those without nephropathy 
with normoalbuminuria [34].
The present study has a number of potential limi-
tations. First, our study was not prospective which 
limited our ability to infer a causal relation between 
HR, blood pressure and renal function parameters. 
Second, ambulatory blood pressure measurement 
is more useful than causal or office blood pressure 
measurement [35]. Lastly, our analyses were based 
on a single measurement of HR, blood pressure and 
albuminuria that may not reflect the relation over 
time.
In conclusion, the results of our study suggest that 
interplay between blood pressure and HR with renal 
function parameters are present even in T1DM with 
normal renal function. The most obvious explana-
tion is that higher HR indicates autonomic dysfunc-
tion and sympathetic nerve activation, which are 
associated with increased albuminuria. Whether the 
detection of elevated resting HR in normoalbuminu-
ric T1DM has predictive value for the development 
of albuminuria and nephropathy needs to be assessed 
in further follow-up studies.
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